Zepbound (tirzepatide) and Wegovy (semaglutide) are both FDA approved injectable medications for chronic weight management in adults with obesity or overweight with at least one weight related condition. The main difference is that Zepbound targets two gut hormones (GLP-1 and GIP) while Wegovy targets only GLP-1, and clinical trials indicate Zepbound may produce greater average weight loss.
That headline difference in weight loss gets most of the attention, but choosing between these two is rarely just about the biggest number. Tolerability, cost, insurance coverage, injection experience, and how your own body responds all matter, and for many people the “best” drug is simply the one they can access affordably and stay on comfortably. This guide walks through each of those dimensions so you can have a more useful conversation with your prescriber rather than fixating on a single trial statistic.
Key Takeaways
- Both Zepbound and Wegovy are GLP-1 receptor agonists used for weight loss, but Zepbound also activates the GIP receptor.
- In trials, Zepbound led to an average weight loss of roughly 15 to 20 percent of body weight, compared to about 12 to 15 percent for Wegovy.
- Both medications require weekly injections alongside a reduced calorie diet and increased physical activity.
- Side effects are similar and include nausea, diarrhea, vomiting, and constipation.
- Cost and insurance coverage vary; Zepbound was approved later and may have different formulary placement.
What are Zepbound and Wegovy?
The simplest way to actually get this done
Superpower is a full-body lab membership that runs 100+ biomarkers, has each result reviewed by a doctor, and tracks your numbers year over year (about $199/year). It is what we point readers to when they would rather get one clean, complete draw than chase single tests one at a time. Here is superpower reviewed in full.
Zepbound and Wegovy are both injectable prescription medications for chronic weight management. Zepbound contains tirzepatide, which is a dual agonist of GLP-1 and GIP receptors. Wegovy contains semaglutide, which is a GLP-1 receptor agonist only. For a deeper look at how these drug classes work, see our explanation of GLP-1 Medications Explained.
It is worth clearing up the brand-name confusion, because these ingredients are sold under more than one name. Semaglutide, the active ingredient in Wegovy, is the same molecule as Ozempic, which is the version approved for type 2 diabetes. Tirzepatide, the active ingredient in Zepbound, is the same molecule as Mounjaro, which is the diabetes version. So Wegovy and Ozempic are semaglutide, and Zepbound and Mounjaro are tirzepatide. The weight-management brands (Wegovy and Zepbound) and the diabetes brands (Ozempic and Mounjaro) differ mainly in their approved use, available doses, and insurance handling, not in the underlying drug. Keeping that straight helps when you read trial results or compare prices, since the diabetes and weight-loss versions are often discussed interchangeably.
How the two-hormone difference actually works
The mechanistic distinction is the reason Zepbound tends to edge out Wegovy on weight loss. Both drugs mimic GLP-1, a gut hormone released after eating that boosts insulin, slows how fast the stomach empties, and signals fullness to the brain. Tirzepatide adds a second action: it also mimics GIP, another gut hormone involved in insulin response and fat metabolism. The prevailing theory is that engaging both pathways produces a stronger combined effect on appetite and energy balance than GLP-1 alone. That said, more mechanism does not guarantee a better result for every individual. Biology varies, and some people lose more on semaglutide than the averages would predict, while others tolerate it far better. The dual mechanism explains the average difference in the trials, not a guaranteed outcome for you.
Are Zepbound and Wegovy the same medication?
No, Zepbound and Wegovy are different medications with different active ingredients and mechanisms of action. Zepbound uses tirzepatide, a dual agonist, while Wegovy uses semaglutide, a single agonist. Both are approved for weight management but have distinct clinical profiles. They are not interchangeable, cannot be swapped dose-for-dose, and are manufactured by different companies, Eli Lilly for Zepbound and Novo Nordisk for Wegovy.
Which medication leads to more weight loss?
Clinical trials suggest Zepbound tends to produce greater average weight loss. In the SURMOUNT-1 trial, people taking the highest dose of tirzepatide lost an average of about 22.5 percent of their body weight after 72 weeks. In the STEP 1 trial, people taking semaglutide lost an average of about 14.9 percent after 68 weeks. A direct head to head comparison study, SURMOUNT-5, found that tirzepatide led to roughly 20 percent weight loss compared to about 13.7 percent with semaglutide over 72 weeks.
Two cautions keep those numbers honest. First, these are averages, and the spread around them is wide. Within any trial, some people lost far more than the average and some lost very little, so a group difference of a few percentage points does not predict which drug will work best for a specific person. Second, trial results come from participants who reached and maintained the highest tolerated doses with structured support. In everyday practice, people who stop early because of side effects, cost, or supply problems will not see trial-level results from either drug. The most reliable predictor of your own outcome is not which molecule you pick but whether you can reach an effective dose and stay on it consistently, which is why tolerability and access matter as much as the raw efficacy gap.
How are the dosing schedules different?
Both medications are injected once weekly under the skin. Wegovy is available in doses of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg. Zepbound is available in doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Each has a gradual dose escalation schedule to minimize side effects.
The reason both start low and climb slowly is tolerance, not caution for its own sake. Beginning at the lowest dose and stepping up every four weeks gives the gut time to adapt, which sharply reduces the nausea and other gastrointestinal effects that would otherwise drive people to quit. It also means neither drug delivers its full effect immediately. Reaching a maintenance dose typically takes several months, so weight loss is a gradual curve rather than a fast drop. A practical implication is that patience during titration pays off. Rushing to the top dose to chase faster results usually just increases side effects and the odds of stopping. Prescribers can and do slow the schedule, hold at a lower dose, or step back down if symptoms are rough, and that flexibility is part of using either drug well.
What are the common side effects of each?
Both medications share similar gastrointestinal side effects. The most common include nausea, diarrhea, vomiting, constipation, abdominal pain, and decreased appetite. These side effects are usually mild to moderate and often improve over time. In trials, roughly 4 to 8 percent of people discontinued either drug due to side effects. Because the mechanisms overlap heavily, the side effect experience is broadly comparable between the two, and there is no strong evidence that one is dramatically gentler than the other on average.
Beyond the common gastrointestinal complaints, both drugs carry the same set of less frequent but more serious warnings, and these apply as a class rather than to one product. Both carry a boxed warning about thyroid C-cell tumors based on rodent studies, so neither should be used by people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Both list risks of pancreatitis, gallbladder problems, kidney injury from dehydration during vomiting or diarrhea, and low blood sugar when combined with certain diabetes medications. There is also growing attention to muscle loss during rapid weight loss on either drug, which is why adequate protein and resistance training are recommended alongside treatment. None of these serious risks meaningfully favor one product over the other; they come with the territory of the drug class.
Practical tips for managing the gut side effects
Most people can blunt the nausea and digestive upset with a few habits rather than quitting. Eating smaller portions and stopping at the first sign of fullness helps, since the drugs slow gastric emptying and overeating on them reliably triggers discomfort. Bland, lower-fat foods tend to sit better than heavy, greasy meals in the first days after a dose increase. Staying hydrated matters both for comfort and to protect the kidneys, especially if vomiting or diarrhea occur. Constipation responds to fiber, fluids, and movement. If symptoms are severe or persistent, the answer is usually to slow the dose escalation with your prescriber rather than to push through or stop abruptly. These strategies apply equally to Zepbound and Wegovy.
How do costs and insurance coverage compare?
Both medications are brand name and expensive without insurance. Wegovy was approved in 2021 and may have more established coverage for weight loss in some plans. Zepbound was approved in 2023 and its coverage is growing. Manufacturer savings programs are available for eligible patients. Typical list prices are in the range of about $1,000 to $1,300 per month, but insurance and savings cards can substantially reduce out of pocket costs for those who qualify.
In real life, cost and access, not the efficacy gap, are what most often decide which drug a person actually ends up on. Coverage for weight-loss medications is inconsistent, and many plans require prior authorization, documentation of a qualifying condition, or step therapy before they will pay. Both manufacturers have offered self-pay options and lower-priced single-dose vial programs for people without coverage, and those offerings change over time, so it is worth checking the current programs directly. Supply has also fluctuated for both drugs, with periodic shortages affecting availability of specific doses. All of this means the sensible approach is to find out what your insurance will actually cover, at what out of pocket cost, and which doses are in stock locally, then choose between Zepbound and Wegovy within those constraints rather than deciding in the abstract.
A note on compounded versions
During shortages, compounded semaglutide and tirzepatide became widely available through telehealth clinics and pharmacies at lower prices, but these are not FDA-approved products, and their quality, potency, and sterility are not guaranteed to the same standard as the branded pens. As shortages resolve, the regulatory allowance for compounding these ingredients has tightened. If cost is pushing you toward a compounded product, it is worth having that conversation with a legitimate clinician who can weigh the real trade-offs, verify the source, and make sure you are getting appropriate lab work and follow-up rather than just a cheaper vial from an unknown supplier.
Zepbound vs Wegovy at a glance
The table below summarizes the practical differences. Treat the weight-loss figures as trial averages, not promises, and remember that individual results vary widely in both directions.
| Feature | Zepbound | Wegovy |
|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide |
| Mechanism | Dual GLP-1 and GIP agonist | GLP-1 agonist only |
| Manufacturer | Eli Lilly | Novo Nordisk |
| Diabetes-branded twin | Mounjaro | Ozempic |
| Dosing | Weekly injection, 2.5 to 15 mg | Weekly injection, 0.25 to 2.4 mg |
| Average trial weight loss | About 15 to 22 percent | About 12 to 15 percent |
| Approval year (weight loss) | 2023 | 2021 |
| Common side effects | Nausea, diarrhea, vomiting, constipation | Nausea, diarrhea, vomiting, constipation |
| Intended duration | Long term | Long term |
How were these numbers actually measured?
It helps to understand where the headline figures come from, because the trial designs shape how you should read them. The SURMOUNT program tested tirzepatide, and SURMOUNT-1 enrolled adults with obesity or overweight without diabetes, following them for 72 weeks on a reduced-calorie diet with increased activity. The STEP program did the same for semaglutide, with STEP 1 running 68 weeks in a comparable population. The most useful comparison is SURMOUNT-5, a head to head trial that put the two drugs against each other in the same study rather than comparing separate trials, and it still favored tirzepatide. Cross-trial comparisons, where you line up results from two different studies, are less reliable because the participants, durations, and protocols differ, so the head to head result carries more weight. Even so, all of these trials paired the drug with lifestyle changes and support, which is the context in which the numbers hold.
Practical differences in using the injection
Day to day, both are once-weekly subcutaneous injections you can give yourself in the abdomen, thigh, or upper arm, and both come in prefilled single-dose pens as well as, in some cases, vials. The injection technique and weekly rhythm are similar enough that switching the mechanics from one to the other is not a hurdle. Storage is comparable too: both are kept refrigerated, with limited room-temperature windows described in their instructions. A small practical point is to pick a consistent day of the week and rotate injection sites to reduce irritation. Neither drug requires blood sugar testing for people using it purely for weight management, unlike insulin, though anyone with diabetes on other glucose-lowering drugs should monitor as advised. These logistics rarely decide the choice, but they reassure people who are nervous about self-injection that the two products feel much the same in the hand.
Which drug is right for you?
There is no universal winner, and the honest answer depends on your priorities and constraints. If maximizing average weight loss is the top goal and you can access it affordably, the trial data give tirzepatide (Zepbound) an edge. If your insurance covers Wegovy well but not Zepbound, or if you tolerate semaglutide better, Wegovy may be the more practical choice, and it still produces substantial loss. People who have already done well on Ozempic for diabetes sometimes prefer to stay within the semaglutide family, while those who plateaued on semaglutide sometimes benefit from switching to the dual-agonist approach. The decision also has to account for what is in stock and what you can sustain long term, since both drugs are intended for ongoing use and stopping tends to bring weight regain.
What often gets lost in the brand comparison is that the scale is only the surface. Whether either drug is the right tool, and whether it is working the way it should, is best judged by the markers underneath your weight: fasting insulin and glucose, HbA1c, lipids including triglycerides, thyroid function, and inflammatory markers. Getting a clear baseline before starting, and rechecking as you go, tells you whether the medication is improving your metabolic health rather than just moving a number, and it can reveal issues like an underactive thyroid or insulin resistance that shape which approach makes sense. That data-first mindset turns the Zepbound-versus-Wegovy question from a guess into an informed choice.
Want a real clinician to run the numbers, not a guess?
Joi + Blokes is a telehealth clinic that prescribes GLP-1 medication (Zepbound, compounded semaglutide and tirzepatide), hormone therapy (TRT, HRT), thyroid care, and peptides after a real lab panel and clinician review, with no membership or consult fee (prescriptions from about $59/month, lab panels from $149). If the scale will not budge, this is where you find out whether insulin, thyroid, or hormones are the real reason. Here is Joi + Blokes reviewed in full.
Frequently Asked Questions
Can I switch from Wegovy to Zepbound?
Switching between these medications is possible but should only be done under a healthcare provider’s guidance. There are no standard switching protocols, and doctors may need to adjust dosing to avoid side effects. It is also important to note that Wegovy and Zepbound have different titration schedules, so a direct dose conversion is not recommended. Most clinicians restart the new drug at a lower dose and re-titrate rather than trying to match the previous dose.
Which medication is better for weight loss maintenance?
Both medications are approved for chronic weight management, meaning they are intended for long term use. Long term trials for Zepbound (SURMOUNT-4) show that continuing treatment maintains weight loss, while stopping leads to regain. Similar results have been seen with Wegovy. Choosing between them for maintenance should be based on individual response, side effect profile, and cost, as both are effective when continued.
Are Zepbound and Wegovy safe for people with type 2 diabetes?
Yes, but there are specific considerations. Zepbound and Wegovy are not approved for type 2 diabetes alone; they are approved for weight management. However, both can improve blood sugar control. People with diabetes should monitor their blood sugar closely, as these medications can lower it and may require adjustments to diabetes medications. Zepbound carries a stronger warning for diabetic retinopathy risk in people with type 2 diabetes. Patients with diabetes are often prescribed the diabetes-branded versions, Mounjaro or Ozempic, instead, depending on coverage.
How soon will I see results on either drug?
Weight loss on both drugs is gradual because the dose climbs slowly over the first several months. Many people notice reduced appetite within the first weeks, but meaningful weight change builds over time as the dose increases toward the maintenance level. The largest trial results were measured at roughly 68 to 72 weeks, so the full effect is a matter of many months rather than weeks. If you have seen little change after reaching a maintenance dose and giving it adequate time, that is a reason to review the plan with your prescriber, not necessarily to switch drugs, since diet, sleep, muscle-preserving exercise, and underlying issues like thyroid function all influence the result.
Do I have to stay on the medication forever?
These drugs treat a chronic condition rather than curing it, so for most people the weight loss is maintained only while treatment continues. Trials in which participants stopped the medication showed substantial regain over the following months, because the underlying biology that drives appetite and weight returns once the drug is gone. Some people work with their clinician to eventually reduce to a lower maintenance dose, and lifestyle changes built during treatment can help, but the current evidence points to long-term use for durable results. This is an important expectation to set before starting either Zepbound or Wegovy.
Do either of these drugs offer benefits beyond weight loss?
Yes, and this is an active and evolving area. Semaglutide has been studied for cardiovascular outcomes, with evidence that it can reduce the risk of major cardiovascular events in certain higher-risk patients, and it has drawn attention for effects on conditions linked to excess weight such as sleep apnea and fatty liver disease. Tirzepatide has shown strong improvements in blood sugar and has been studied in obstructive sleep apnea as well. Both improve metabolic markers like blood glucose and often lipids as weight comes down. The specific approved indications differ between the brands and continue to expand as trials report out, so if you have a condition beyond weight, such as heart disease risk or sleep apnea, that is worth raising with your prescriber, because it may tip the choice toward one drug and may also affect insurance coverage.
Is the extra GIP action in Zepbound better for everyone?
Not necessarily. The dual GLP-1 and GIP mechanism explains why tirzepatide produced greater average weight loss in trials, but averages hide a lot of individual variation. Some people respond very well to semaglutide and lose more than the group average, while others tolerate one drug far better than the other for reasons that are not fully predictable in advance. The extra mechanism does not translate into a guaranteed personal advantage, and it does not make Zepbound clearly gentler or safer, since the two share the same class-wide risks. The practical takeaway is to treat the mechanism difference as one factor among several, alongside tolerability, cost, coverage, and how your own body responds, rather than as a decisive reason to pick one over the other.
This article is for general information and is not medical advice. See our Medical Disclaimer.
